Background: Acacia catechu is an important traditional medicinal plant that has been used to manage several ailments. Many in vitro and in vivo studies have demonstrated that it exhibits chemopreventive and antineoplastic effects by modulating diverse signaling pathways and molecular targets involved in cancer progression. This review attempts to systematically investigate the anticancer mechanisms of A. catechu, encompassing antiapoptotic, antioxidant, and antiproliferative activities. Material and Methods: This review was conducted using scientific databases such as Scopus, Web of Science, and Google Scholar, covering the studies from 2000 to 2024. The PRISMA methodology was applied, using the keywords A. catechu, phytoconstituents, and cancer. Results: A total of 39 studies were compiled from various databases that cited the biological use of A. catechu. The plant has an abundance of phenolic compounds, including catechin, epicatechin, epigallocatechin-3-O-gallate, and epicatechin-3-O-gallate, which show strong anticancer activities. The anticancer potential of A. catechu is explained as it regulates several modulators like reactive oxygen species and cytokines, and downregulates oncogenic molecules like c-myc and various signaling pathways, such as c-Jun and NF-κB. Conclusions: Our findings suggest that A. catechu and its bioactive constituents have the potential for cancer prevention and therapy. However, further mechanistic investigations using pure compounds, along with preclinical and clinical trials, are essential to translate this potential into clinical applications.
17 October 2026 in Indian Journal of Gynecologic Oncology
Ovarian cancer (OC) is one of the most lethal malignancies, primarily due to late-stage diagnosis, biological heterogeneity, and high rates of recurrence. Advances in precision oncology have underscored the importance of molecular testing to improve risk stratification, guide targeted therapies and prognostic assessment. Next-generation sequencing (NGS) has emerged as a revolutionary technology that has made multi-gene analysis of various specimens, such as tumor tissue and liquid biopsies possible. NGS has become an integral part of OC management as it has a crucial role in the identification of genetic and somatic mutations. However, several factors, such as variability in test strategies, specimen selection, analysis time, and clinical applications hinder its consistent use in clinical settings. This review highlights existing evidence regarding the clinical utility of NGS-based molecular testing in OC, encompassing its uses in diagnosis, treatment stratification, disease monitoring and evaluation of hereditary risk. It addresses the molecular complexity of various histological subtypes, with a focus on the important genomic alterations, such as homologous recombination repair defect and BRCA1/2 pathogenic variants. The strengths and limitations of various bio-specimens are discussed in relation to their performance and clinical applicability. It also discusses the most appropriate timings and accessible methodologies of molecular testing, ranging from traditional to high-throughput NGS systems. The main obstacles to large-scale deployment, as well as the new models of integration, are outlined with the focus on the new role of the artificial intelligence-led decision support system.